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ABSTRACT
Neurologic disease diagnosis and treatment is challenging. Multiple Sclerosis 
(MS) is a demyelinating autoimmune disease with few clinical forms and uncertain 
etiology. Current studies suggest that it is likely caused by infection(s) triggering a 
systemic immune response resulting in antigen/non-antigen-related autoimmune 
response in central nervous system (CNS). New therapeutic approaches are needed. 
Secreted by viable embryos, PreImplantation Factor (PIF) possesses a local and 
systemic immunity regulatory role. Synthetic PIF (PIF) duplicates endogenous 
peptide’s protective effect in pre-clinical autoimmune and transplantation models. 
PIF protects against brain hypoxia-ischemia by directly targeting microglia and 
neurons. In chronic experimental autoimmune encephalitis (EAE) model PIF reverses 
paralysis while promoting neural repair. Herein we report that PIF directly promotes 
brain re-myelination and reverses paralysis in relapsing remitting EAE MS model. PIF 
crosses the blood-brain barrier targeting microglia. Systemically, PIF decreases pro-
inflammatory IL23/IL17 cytokines, while preserving CNS-specific T-cell repertoire. 
Global brain gene analysis revealed that PIF regulates critical Na+/K+/Ca++ ions, amino 
acid and glucose transport genes expression. Further, PIF modulates oxidative stress, 
DNA methylation, cell cycle regulation, and protein ubiquitination while regulating 
multiple genes. In cultured astrocytes, PIF promotes BDNF-myelin synthesis promoter 
and SLC2A1 (glucose transport) while reducing deleterious E2F5, and HSP90ab1 
(oxidative stress) genes expression. In cultured microglia, PIF increases anti-
inflammatory IL10 while reducing pro-inflammatory IFNγ expression. Collectively, 
PIF promotes brain re-myelination and neuroprotection in relapsing remitting EAE MS 
model. Coupled with ongoing, Fast-Track FDA approved clinical trial, NCT#02239562 
(immune disorder), current data supports PIF’s translation for neurodegenerative 
disorders therapy.
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INTRODUCTION
Immune balance is a key aspect of the physiological 
development and function of an organism. Imbalance of 
this essential homeostasis can lead to autoimmune disease 
(AD). Similarly, effective embryo-maternal crosstalk 
leading to controlled immunomodulation is essential for 
successful outcome of pregnancy [1]. The semi-allogeneic 
fetus (transplant) is not rejected by the mother, achieving 
“transplant tolerance”. Concurrently, protection against 
pathogens (regulated immunity) remains largely preserved 
thus reflecting a close to optimal immune milieu. 
Seemingly, paradoxically, in the case of an immune 
challenge, such as AD, the mechanisms of this maternal 
immune status are able to mitigate or even reverse the AD. 
Several ADs, such as rheumatoid arthritis [2] and multiple 
sclerosis (MS) [3, 4], actually improve during pregnancy, 
while miscarriage may exacerbate their symptoms [3]. 
Protection against AD, however, is pregnancy-specific 
and only temporary, since shortly following parturition 
they tend to flare up [4–8]. Not surprisingly, the search 
for pregnancy-specific compounds, that are suitable for 
clinical use, is ongoing [4, 5].
Ideally, such a compound would regulate both 
local and systemic immunity, in a safe manner, since AD 
impairs both. Specifically, for MS/neuroinflammation, 
such a drug would promote brain myelination and reverse 
paralysis through integrated local and systemic action. 
Such is the premise of the use of PreImplantation Factor 
(PIF*). PIF is an endogenous peptide, secreted by viable 
embryos and absent in non-viable ones. PIF is expressed 
from the earliest stages of gestation and is essential to 
pregnancy [9–13]. Further, PIF protects and supports 
embryo development [14] and promotes implantation and 
trophoblast invasion [12, 15–18]. Mechanistically, PIF 
regulates systemic immunity, targeting the innate arm, 
while only minimally affecting quiescent lymphocyte 
activity. Following peripheral blood mononuclear cell 
activation, PIF blocks the mixed lymphocyte reaction 
and proliferation, leading to a Th2 cytokine bias typical 
of pregnancy while not concurrently suppressing the 
beneficial Th1 type response [17, 19, 20]. In addition, PIF 
reduces K+ flux by targeting the cortisone binding site 
(Kv1.3b channel) [21] while targeting PDI/thioredoxin 
and heat shock proteins to prevent oxidative stress and 
protein misfolding [19]. PIF regulates systemic immunity 
[19, 20, 22]. PIF reduces the cytotoxicity of NK cells as 
well [9, 17, 19].
Consistent with the view that a pregnancy derived 
compound PIF can also be effective beyond pregnancy, 
a synthetic PIF (PIF) was successfully used in non-
pregnant animal models. For example, PIF administration 
prevents development of Type 1 diabetes mellitus [23], 
atherosclerosis [21], and graft vs. host disease [24] as 
well protects against acute radiation induced pathologies 
[25]. In neurodegeneration models, PIF passes the blood-
brain barrier, protects the immature brain after injury, and 
targets both the microglia and neurons [26, 27]. In an adult 
MS-experimental autoimmune encephalomyelitis (EAE) 
model, PIF reverses severe paralysis while promoting/
maintaining neural repair long-term [28]. All in all, PIF 
provides neuroprotection from the embryonal stage 
(against adverse maternal environment), to the newborn 
and adult through an integrated local and systemic effect 
[1, 18].
Current MS therapy aims to reduce the progressive 
neural damage and minimize its clinical manifestations. 
For acute attacks, steroids and β-interferon are used [29]. 
To reduce the frequency of paralytic attacks glatiramer 
acetate, natalizumab, linomide, fingolimod, and dimethyl 
fumarate are useful [30–34]. For the treatment of 
progressive MS, mitoxantrone and cladribine may be 
used [35]. Stem cell transplantation for MS therapy is still 
experimental. The customarily used preclinical models 
that led to the approved drugs do not fully represent the 
MS spectrum. EAE, for example, can be induced by 
various CNS peptides or by transfer of encephalitogenic 
T-cells [36–38], each only reproduces a specific aspect 
of clinical MS. Thus, no single current EAE model 
accurately recapitulates the clinical MS spectrum [39]. 
In MS, genetics also plays a significant role as seen by 
the association between MHC region immune responses 
and the disease [40, 41]. However, the low concordance 
between mono-zygotic twins indicates a predominantly 
important role also for environmental factors. One crucial 
factor of these is bacterial infection. For a classical EAE, 
mycobacterium-derived antigen motifs are required 
leading to polarization of CD4+ and CD8+ T-cells, and 
trafficking of CNS specific T cells [42–44]. Notably, MS 
improvement (in EAE models) was noted both in the white 
and grey matter of the brain [45, 46]. To test PIF induced 
protective effects, we used a chimeric M. smegmatis 
bacterium producing proteolipid protein peptide (PLP) 
139-151 (p139) fused with MPT64 to induce a clinically-
relevant RR-EAE model [43]. We examined PIF effects 
on brain myelination, clinical score and global genome 
expression. Further, PIF effects on systemic cytokine 
expression and lymph node T-cell repertoire was 
determined. From a clinical point of view, cGMP PIF 
(human grade) is already being used clinically in FAST-
TRACK awarded, FDA-approved, University-sponsored 
clinical trials to assess PIF drug safety and efficacy in an 
autoimmune disorder (ClinicalTrials.gov NCT02239562).
RESULTS
Both continuous and intermittent PIF 
administration consistently ameliorate RR-EAE
Given that early MS can start as an acute paralytic 
attack and that PIF was shown to prevent and reverse 
paralysis in a classic antigen driven EAE model [28], we 
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tested continuous PIF administration using the infectious/
inflammatory RR-EAE model (Figure 1A). The RR-
EAE model is utilitarian for anti-MS drug development 
and although M. smegmatis bacteria are rapidly cleared, 
neuroinflammation becomes progressive, reflecting 
advanced stage disease [43]. In addition, we also have 
shown that the induction of EAE is dependent on the ability 
of the infection to drive a CNS-specific immune response, 
since infection with a recombinant M. smegmatis not 
expressing Plp 139-151 does not result in clinical EAE. To 
mimic a clinical approach, we treated mice with PIF (0.75 
mg/kg i.p daily) or PBS [28]. As expected, starting on the 
third day post-inoculation PIF significantly decreased the 
resulting clinical score (Figure 1A) of injured animals. 
Maximal decrease was present at the acute (early) disease 
phase. Mean clinical score and average total disease score 
(ATDS) were significantly lower compared to control 
group. The maximal decrease was noted after a couple of 
days of PIF administration, at the acute phase of disease. 
The mean clinical score was lower than in vehicle treated 
controls throughout and until the end of the experiment. The 
ATDS was significantly decreased by PIF administration 
(PBS 29.25 vs PIF 21.75; p= 0.01, Wilcoxon-Mann-
Whitney test). The composite effect of PIF on AUC are 
shown (Supplementary Figure 1). Together, continuous PIF 
administration can consistently ameliorate post-infective 
acute paralysis.
Again, attempting to mimic human MS, which 
has a relapsing-remitting course, we next examined 
whether intermittent PIF administration, as needed when 
symptomatic, is also effective (Figure 1B). After RR-EAE 
induction PIF treatment was only during the active state of 
disease while interrupting treatment during the remission 
period. Again, PIF significantly decreased the clinical 
score compared with controls (ATDS: PBS 53.31 vs. 
PIF 41.05; p=0.032, Wilcoxon-Mann-Whitney test). The 
improved clinical score persisted for 20 days post-therapy 
and remarkably even after 70 days from inoculation the 
protective effect of PIF remained significant.
In order to determine whether a higher PIF dose 
would further ameliorate disease course, mice were treated 
intermittently on days 5-27 and then, on days 44-62- with 
PIF (1.5 mg/Kg) or with vehicle only, while continuing to 
monitor the EAE course. (Figure 1C) The PIF treated mice 
had a significantly milder disease score (ATSD: PBS 39.79 
vs. PIF 34.92; p=0.026) than control mice. However, the 
increased PIF dose did not further improve ATDS versus 
the lower dose, confirming that the optimal effects are 
obtained in a physiologic concentration [1]. Overall data 
reveal that PIF is effective in reducing paralysis in a 
clinically realistic acute MS model long-term.
PIF promotes brain re-myelination
Given that PIF ameliorates RR-EAE (Figure 1A–1C) 
and that the myelination deficit is a hallmark of MS, 
next we tested PIF effects on myelin expression. Indeed, 
the exposure to the M. smegmatis challenge (injury) 
resulted in a significant reduction of myelin positive cells 
(Figure 2A and 2B: compare Injury versus Control: naïve 
mice), confirming the previously reported observations 
[43]. Importantly, PIF treatment resulted in significant 
amelioration of the induced myelination loss (Figure 
2A and 2B: compares Injury+PIF versus Injury alone). 
The results in the PIF treatment group are similar to 
that observed in controls (Figure 2A and 2B: compare 
Injury+PIF to Control). We hypothesize that the observed 
effect on brain myelination and the previously reported 
effect on spinal cord myelination [28] are mainly due to 
modulation of the inflammatory responses. Thus, whether 
PIF directly targets the brain to promote re-myelination 
was tested next.
PIF crosses the BBB and targets brain microglia
It was previously shown that following brain 
trauma PIF crosses the BBB to target microglia and 
neurons [26]. To assess whether in chronic RR-EAE PIF 
can also cross the BBB to reach the CNS was determined 
next. 11 week old female SJL mice, previously infected 
with rMSp139, and at a chronic phase of disease (>62 
days after infection) treated with PIF or PBS for 3 
weeks were injected with a single dose of FITC-PIF, 
PBS, and scrambled-PIF-FITC (inactive peptide). In the 
PBS injected mice (Figure 3A) the Iba-1 positive cells 
(microglia) showed predominantly amoeboid state and 
negative PIF staining. In line with previous reports [26], 
in PIF treated animals microglia was predominantly in 
ramified state and PIF positive (Figure 3B). Scrambled 
PIF-FITC was PIF negative (Figure 3C). Thus we 
conclude that PIF crosses the BBB and targets the brain 
during the chronic inflammation phase. These results 
support PIF use for targeted therapy in MS.
PIF reduces pro-inflammatory cytokines in 
lymph node while not altering T-cell recruitment
Neuroinflammation is a progressive process where 
in early stages the innate immune system is the main 
participant but as inflammation progresses the adaptive 
arm of immunity becomes functional. Therefore, we 
initially tested the effect of PIF in early-stage disease 
where systemic cytokines may be affected. Given that 
the systemic effects of PIF are well described [24] [28], 
we tested the gene expression of crucial cytokines (acute 
time point of the injury at day 10) (Figure 4). Indeed, we 
detected significantly reduced Interleukin (IL)-23 and 
IL-17a cytokine expression in the lymph nodes. Notably, 
IL-23 is part of the innate immunity (produced mainly 
by dendritic cells and macrophages) and promotes the 
expansion of CD4+ T helper (Th)-cells secreting IL-
17 (Th17) which is a potent pro-inflammatory cytokine 
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[47] IL-17 plays a dominant role in MS (and EAE) and 
in several other autoimmune diseases [48]. Further, the 
ability of PIF to modulate IL-23 while preserving IL-12B 
expression (which regulates polarization of T-cells to Th1 
phenotype) may explain pregnancy-induced protection 
against autoimmunity concurrent with preservation of 
anti-pathogenic responses.
The adaptive arm of immunity may be affected 
in RR-EAE as well. Therefore, we examined the effect 
of PIF or PBS injections administered until day 30 of 
Figure 1: Continuous and intermittent PIF administration reduces clinical score (RR-EAE model). SJL mice (4-7 per 
group) were infected sc with 4x106 CFU of live recombinant M Smegmatis expressing a recombinant chimeric protein MPT64-PLP139-151 
(rMSp139), as previously published [43]. Starting on day 3 after infection, mice were treated daily with PIF (closed symbols and black bars) 
or vehicle only (PBS, open symbols and white bars). (A) Disease course and average total score of disease in mice treated continuously until 
day 50 after infection with 0.75 mg/Kg of PIF (n=6) or with vehicle only (n=4) (B) Disease course and average total score of disease in mice 
treated from day 3 until day 18 and then from day 51 until day 70 with 0.75 mg/Kg of PIF (n=6) or with vehicle only (n=4). (C) Disease 
course and average total score of disease in mice treated from day 3 until day 25 and then from day 51 until day 65 with 1.5 mg/Kg of PIF 
(n=7) or with vehicle only (n=6). Disease score was monitored by two independent examiners, blinded with respect to treatment. *p< 0.05; 
Mann-Whitney test. PIF: PreImplantation Factor, ATDS: average total disease score.
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the study. Following sacrifice isolated spleen cells were 
cultured and activated by antigen PLP-p139 or control. We 
aimed to characterize the immunization-induced systemic 
T-cell repertoire epitopes involved in MS: 1. CD4+ cells 
were characterized by the (Vb 4-Jb1.6; Vb10-Jb1.1) TCR 
rearrangements [42]. 2. The CD8+ cells were characterized 
by the (Vb17-Jb1.6; Vb20-Jb2.3) rearrangements [43] 
specific for PLP-p139. 3. We also analyzed the T-cell 
Figure 3: PIF targets microglia in the brain. SJL mice previously infected with rMSp139 and in late phase of chronic disease (> 60 
days after infection) treated with PIF or PBS for 3 weeks were injected with a single FITC-PIF or PBS dose and sacrificed 3 hours later. We 
used FITC-scrambled PIF as negative control as well. Brains were prepared for histology. (A) In the PBS injected mice the Iba-1 positive 
cells (microglia) showed predominantly amoeboid state and negative PIF staining. Right panels show Iba-1 positive cell (upper), negative 
PIF immunofluorescence (middle) and merged images (lower). (B) In PIF treated animals microglia was predominantly in ramified state 
and PIF positive. Right panels show Iba-1 positive cell (upper), positive PIF immunofluorescence (middle) and merged images (lower). 
(C) In the PBS injected mice with FITC-scrambled PIF (negative control) the Iba-1 positive cells (microglia) showed predominantly 
amoeboid state and expectantly negative PIF staining. Right panels show Iba-1 positive cell (upper), negative PIF immunofluorescence 
(middle) and merged images (lower). Scale bar 50 µm.
Figure 2: PIF promotes brain re-myelination. PIF effect on myelin expression was compared to vehicle treated control and naïve SJL 
mice. Briefly, at day 28-30 after RR-EAE induction (control n=3; Injury n=5; Injury+PIF n=8) mice fixed brains were embedded in paraffin 
and sectioned into 7µm slices. Slides were stained in Cresyl violet (Nissl body staining for neuronal structure and gross brain morphology) 
and Luxol Fast Blue revealing areas of myelination in the subcortical white matter. (A) Representative images of subcortical white matter 
comparing the three groups. Upper panel shows the brain morphology and myelination. PIF treated injured brains (Injury+PIF) are similar 
to naïve mice (control) and vehicle treated injured brains (Injury) show impaired myelination in the subcortical region. Lower panels: 
Representative images of the subcortical region (blue staining: luxol fast blue) display PIF`s induced myelination (compare Injury+PIF 
versus Injury and Injury versus Control). (B) Quantitative analysis of myelin positive cells in the groups. PIF treatment results in restored 
myelination in the brain. *p<0.05 and ** p<0.01. PIF: PreImplantation Factor; scale bar: 100µm.
Oncotarget21839www.impactjournals.com/oncotarget
repertoire present in spontaneously activated naïve mice 
(Vb18-Jb1.2; Vb19-Jb1.2 rearrangements) [48]. Figure 5 
summarizes that PIF did not modify T-cells recruitment 
as compared with PBS treated mice. We hypothesize that 
PIF does not affect the systemic T cell lineage to maintain 
the anti-pathogenic activity of cells that do not access the 
CNS and therefore are not pathogenic for development of 
RR-EAE.
Figure 4: PIF modulates cytokine expression in draining lymph nodes. SJL mice (5 each group) were infected with rMSp139 
and treated daily with 0.75 mg/Kg of PIF (black bars) or vehicle only (white bars). Ten days later, cells from draining lymph nodes 
were obtained and cultured for 3 hours. Levels of mRNA specific for the indicated cytokines and transcription factors were measured by 
quantitative RT-PCR. PIF reduced the expression of IL-17 and IL23 significantly. *p<0.05 (Mann-Whitney Test); PIF: PreImplantation 
Factor.
Figure 5: PIF does not modulate splenic T cell repertoire. SJL mice (7 each group) were infected sc with rMSp139 and treated 
daily with 0.75 mg/Kg PIF or vehicle (PBS). Thirty days later, cells from spleen were obtained and cultured in the presence or absence of 
p139. mRNA was obtained and submitted to TCR BV-BJ spectratyping for the shared rearrangements characterizing the induced CD4+ 
T cells specific for p139 (Vb 4-Jb1.6; Vb10-Jb1.1), the T cells spontaneously responding to this epitope (Vb18-Jb1.2; Vb19-Jb1.2), and 
the induced CD8+ T cells specific for p139 (Vb17-Jb1.6; Vb20-Jb2.3). Each column reports data from one individual mouse, and a black 
square indicates the detection of T cells bearing the indicated TCR rearrangement. TCR: T cell repertoire; PIF: PreImplantation Factor.
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PIF regulates genes involved in solute transport, 
oxidative stress, and protein degradation in the 
brain
In the classic EAE model we found that PIF had 
a major regulatory effect on the spinal cord genome and 
proteome [28]. Since in this study PIF led to restored 
myelination and reduced paralysis we examined the 
effect on the global brain gene expression as well. We 
detected a total of 168 genes which expression were 
increased or decreased by PIF as compared with the 
PBS treated group (p<0.05 (Supplementary Table 1). 
Ingenuity-based pathway analysis demonstrated that 
effect by PIF on neuronal disorders had the highest 
ranking as determined by the Z score (Table 1). This was 
followed by a significant effect on movement disorders 
and paralysis which supports our results (Figure 1–3). 
Detailed pathway analysis (Figure 6 and 7) showed 
that PIF modulates multiple genes involved in hypoxia 
and protein degradation induced by ubiquitination. PIF 
induced effects are visualized in a heatmap analysis as 
well (Supplementary Figure 2). The data revealed that 
PIF affected pathways involved in protein formation, 
EF4A1– RNA binding and degradation through Rnf13 
(E3 Ubiquitin-Protein Ligase) pathway. The largest group 
of genes identified known to be critical for brain function 
are several solute carriers (SLC7a10, SLC2a1, SLC25a11, 
SLC7a14, and SLC24a3) involved in Na+/K+/Ca++ ions 
exchange, while others regulate glucose and amino acid 
transport.
The global gene analysis further revealed that PIF 
reduces several genes involved in oxidative stress and 
protein misfolding (Figure 6, Supplementary Tables 1, 
2). The reduced heat shock proteins and ubiquitination 
genes (CUL1, UBE2E1, UBE2Q1, PSMD1, HSP40, 
HSP90AB1, SUMO1) was coupled with (USP54, an 
ubiquitin peptidase) up-regulation which may protect 
against protein degradation [49]. PIF also regulated 
EIF2 eukaryotic initiation factor genes (EIF2B1, EIF3I, 
EIF4A1, PPP1CB, RPL22) to potentially reduce cellular 
stress. This pathway also initiates methionyl-tRNA and 
mRNA transfer to the 40S ribosomal subunit forming 
the 48S complex required for effective protein synthesis 
[49]. Notably, PIF also regulates aspargine biosynthesis 
pathway, which is altered in cases of microcephaly and is 
associated with progressive encephalopathy [50]. Among 
top ranking genes (Supplementary Table 1) PIF promoted 
spermine oxidase expression, where the encoded protein 
improves neurotransmission via cell-surface receptor and 
regulates reactive oxygen species [51]. PIF also promoted 
StAR expression involved in acute regulation of steroid 
hormone synthesis converting cholesterol to pregnenolone. 
In the brain StAR is restricted to specific neurons where 
it has neuroprotective effects. Finally, increased ARRB2, 
arrestin beta promotes synaptic receptors and MCF2L 
axonal transport in the brain [52]. Supplementary Figure 
3 shows a comprehensive analysis of PIF induced action-
based on Ingenuity program. Expectantly, PIF modulates 
multiple genes involved in neurologic diseases, skeletal 
and muscle disorders, and Cancer disorders [22–24, 
26, 27]. Multiple molecular and cellular functions and 
physiological and system development and function 
genes are modulated by PIF as well. In line with the 
notion of PIF as essential pregnancy peptide embryonic 
development and DNA replication, recombination, and 
repair genes are top ranked [1]. Detailed analysis is 
presented in Supplementary Tables 1 and 2. Overall the 
gene data reveal potential mechanisms involved in PIF 
induced neuroprotection.
PIF-induced upstream regulation involves 
MYCN (ERK/MAPK signaling) and cortisol 
binding site (NR3C1)
MYCN- neuroblastoma homolog gene regulates 
cell proliferation, survival, and apoptosis: (Supplementary 
Table 2) This upstream regulator involved in the myc 
signaling and is regulated by let-7 microRNA. Let-7 is 
down-regulated in the brain by PIF, thereby protecting 
against hypoxic ischemic brain damage [26]. PIF 
increased both (RPL22, SLC2A1) genes expression. 
Since these genes are upregulated by MYCN, indicates 
that this pathway is also regulated by PIF. In contrast, 
PIF decreased the expression of (NCL, E2F5, HSPAB1, 
EIF4A1, RBBP7, TPI1, ACTB) genes. Since MYCN 
activates (NCL, E2F5, HSP90AB1, and EIF4A1) genes 
indicates that PIF down-regulates MYCN effect. Finally, 
in case of ACTB both MYCN and PIF act in a similar 
manner to down-regulate the same gene. Also MYCN 
targets NCL a gene which expression is decreased by 
PIF. The second ranking upstream regulator is NR3C1 
a glucocorticoid receptor that plays a major role in cell 
proliferation, remodeling and apoptosis: NR3C1 is a 
Table 1: PIF protects against brain infection/
inflammation: genome Z score analysis (Ingenuity)
CONDITION Z log
Neuromuscular disease 3.209
Movement disorders 3.095
Progressive motor Neuropathy 3.02
Disorders of basal ganglia 2.62
Ranking is based on the score that determines the 
highest association within the pathways among the gene 
clusters. This was determined by using the 168 genes 
that up or down regulated (Supplementary Table 1). 
When the top disease was ranked 40 different genes were 
associated followed by 30 genes regulated by movement 
disorders: skeletal and muscular. Further data provided in 
Supplementary Table 2.
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homodimer that interacts with HSP90, a PIF target [22]. 
PIF Increased the expression of: (USP54, BRD2, ARRB2) 
and decreased the expression of (WDR37, CUL1, SIAHA, 
HIC2. HSP90AB1, ATG12, PTP4A2, TM2D2, NMT1, 
ABI1, ACTB) genes. NR3C1 also interacts with SUMO1, 
an ubiquitin related gene which expression is decreased by 
PIF. Overall this data implies PIF involvement in MYC as 
well as glucocorticoid signaling, reflecting regulation of 
inflammatory response in the brain.
PIF promotes BDNF, SLC2A1, and reduces 
HSP90AB1, and E2F5 genes expression in 
primary astrocytes
Originally astrocytes were viewed as support cells for 
the brain, however, as recently indicated they play a major role 
in CNS microarchitecture and neural cells development. Also 
as recently shown these cells greatly facilitate interneuron 
communication [53]. Moreover, astrocytes protect the brain 
by releasing cytokines and neurotrophic factors; importantly, 
the brain derived neurotrophic factor (BDNF) [54]. These 
cells through BDNF action were shown to restore brain 
myelination in a neuroinflammatory disease model [55]. We 
found that PIF promoted the expression of BDNF by cultured 
primary astrocytes in a dose dependent manner (Figure 8). 
Therefore the observed effect on brain re-myelination (Figure 
3) is partially exerted by PIF targeting brain astrocytes which 
are associated with increased BDNF expression. Whether 
the effect of PIF on brain genes expression (Supplementary 
Tables 1 and 2) is exerted by targeting local astrocytes was 
examined next. PIF regulates several brain solute transporters 
including SLC2A1 which is involved in glucose transport. 
We tested PIF effect in primary astrocytes cell culture 
documenting a dose dependent increase in SLC2A1 gene 
expression, thus confirming the brain genome data (Figure 8). 
In contrast, PIF reduced HSP90AB1 expression preventing 
protein degradation. Notably the protein product is a major 
PIF target [20, 22]. PIF also reduced E2F5 expression (a cell 
cycle protein) (Figure 8). This gene is expressed in the spinal 
cord following post-traumatic injury [56]. Thus PIF may 
regulate the expression of genes in the brain by targeting local 
astrocytes.
PIF promotes IL10 and reduces IFNγ expression 
by primary microglia cultures
In the current study PIF was shown to directly target 
microglia (Figure 3). Whether PIF also regulates these 
brain derived primary macrophages was tested next. In 
microglia cell lines PIF promotes IL10 [26, 27]. Herein the 
Figure 6: PIF effect of global brain genome pathways (Ingenuity analysis). Schematic pathways that are significantly affected 
by PIF and their interaction. Leading among them was the ubiquitin pathway that is responsible for protein degradation which was down-
regulated by PIF. This was coupled with reduction in hypoxia signaling that creates vascular inflammation thereby the oxidative stress 
is reduced as well. On the other hand, the EIF2 signaling pathway increased which is responsible for the promotion of protein synthesis.
Oncotarget21842www.impactjournals.com/oncotarget
effect of PIF was tested on primary mouse cells examining 
effect on IL10 and Interferon (IFN)γ cytokines secretion 
(Figure 9). Data documented the dual action of PIF as PIF 
increased the pro-tolerance IL10 while reducing the pro-
inflammatory cytokine IFNγ secretion. Overall the cell 
based data support PIF’s direct effect on the brain.
DISCUSSION
There is an urgent need to develop safe, easy to 
administer and effective MS/neuroinflammation therapy. 
Due to the sub-clinical and indolent nature of progressive 
neurologic disorders they are especially difficult to 
diagnose early and treat. In the MS brain the loss of 
myelin is key evidence for disease progression therefore 
safe reversal would be a major advance. Our major 
finding is that PIF targets brain microglia to promote re-
myelination in a post-infectious clinically realistic RR-
EAE model. Addressing critical aspects of the disease 
through an integrated action PIF lowered the paralysis 
score while reducing systemic inflammation. Global brain 
gene analysis revealed that PIF promoted expression of 
Na+/K+/Ca++, glucose and amino acid transporters, 
while reducing oxidative stress and protein degradation. 
In primary astrocytes culture PIF promoted BDNF 
expression – key for myelin synthesis and in primary 
microglia increased IL10 while reducing IFNγ cytokines 
secretion. Together our data support PIF testing in a 
clinical setting for treatment of MS.
MS has variable clinical course and tends to 
be progressive. As PIF is effective long-term when 
administration is either continuous or episodic, it supports 
the clinical potential. PIF therapy in early stage of the 
disease or even when progressive may be envisaged. 
Since intermittent PIF administration led to reduced 
paralysis which lasted ~80 days- it supports potential 
long-term efficacy, perhaps for years in patients. A 
similar long-term protection was found using PIF in 
the classic EAE model [28]. In our study a single daily, 
low physiologic PIF regimen was found to be effective. 
Such minimally invasive dosing is expected to increase 
patients’ compliance. Collectively, PIF protects against 
neuroinflammation long-term irrespective if it is antigen 
driven or is of infectious origin.
Figure 7: PIF effect on global genome (Ingenuity statistics). Evaluation of the pathways involved describing the effect PIF 
whether it is up or down regulated as well the associated level of significance. Namely the reduction in ubiquitination and EIF2 signaling 
were the most pronounced. On the other hand, the most remarkable increase was present in asparagine biosynthesis which protects against 
vascular damage.
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Figure 8: Figure 8: PIF promotes BDNF, SLC2A1, and reduces HSP90AB1, and E2F5 expression in astrocytes. Primary 
astrocytes were cultured with increasing PIF concentrations up to 48 hours. PIF promotes BDNF expression (myelin synthesis inducer), 
SLC2A1 expression (glucose transporter) while reducing HSP90AB1 expression (oxidative stress), and E2F5 expression (neuro-injury 
activated). mRNA levels were determined using RT-PCR of the specific genes compared to S12 expression. For each factor the control 
levels were set as 1 and the expression of the treated samples was compared to the control. *** p<0.001. PIF: PreImplantation Factor.
Figure 9: PIF promotes IL10 and reduces IFNγ expression in microglia cultures. Primary microglial cells were cultured with 
increasing PIF concentrations up to 48 hours. PIF increased anti-inflammatory IL10 while reducing pro-inflammatory IFNγ expression in a 
dose dependent manner. mRNA levels were determined using RT-PCR of the specific genes compared to S12 expression. For each factor the 
control levels were set as 1 and the expression of the treated samples was compared to the control *** p<0.001. PIF: PreImplantation Factor.
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Although infection by the Smegmatis bacteria 
combined with PLP activates the immune system, these 
bacteria are rapidly eliminated while the inflammatory 
response remains. As such the post-infectious- 
inflammatory EAE (RR-EAE) replicates clinical MS 
features as shown by the significant demyelination of the 
brain. Remarkably, PIF restored myelination in the brain. 
This key finding addresses a pathology which is difficult to 
achieve by current therapy especially when MS symptoms 
become progressive. In our RR-EAE model the focus was 
the brain and finding that PIF directly targets the microglia 
(immune element) is crucial. This is highly relevant since 
PIF was administered during the chronic phase of the 
disease and apparently at that point the BBB was intact. 
On the other hand, current drugs used for the treatment 
of neurologic diseases have to be of small size or lipid 
soluble in order to cross by trans-membrane diffusion. 
The use of transporters may improve larger proteins and 
peptides access to the CNS [57]. In the hypoxic-ischemic 
encephalopathy model PIF also directly targets brain 
microglia and neurons while is rapidly cleared from the 
circulation [26, 27]. Thus PIF directly targets the brain 
which leads to re-myelination and reduced paralysis.
Immune disorders, including neuroinflammation/
MS have both local and systemic components. In order 
to prevent relapse, they both have to be addressed. PIF 
directly targets the systemic immunity in vitro and these 
observations were confirmed also in vivo [17, 19, 20, 23, 
28]. The lower IL-23 and IL-17 cytokines expression 
in lymph nodes reflect systemic protection. Similar to 
the IL-23 dimer circulating IL-12 levels were reduced 
by PIF in the classic EAE model preventing paralysis 
development [28]. PIF targets macrophages which 
secrete IL-23 and IL-12 cytokines [24] [58]. IL-17 plays 
a key role in autoimmunity, and PIF reduced this pro-
inflammatory cytokine levels in PLP-activated splenocytes 
[28]. Interestingly, the T-cell repertoire recruitment was 
not affected by PIF. Thus, the innate (at the acute phase 
at day 10) but not the adaptive arm of immunity (at sub-
acute phase at day 30) are affected by PIF. Such duality 
of action preserves the beneficial anti-pathogenic effect. 
The relative importance of PIF induced systemic as 
compared with CNS protection cannot be determined at 
present and will be addressed in future studies. Overall 
PIF’s integrated systemic and/or central protection leads 
to amelioration of the clinical score.
In classic EAE contrary to our current RR-EAE 
model, the focus was the spinal cord while in MS brain 
inflammation is dominant. Mechanistically in classic 
EAE in the spinal cord PIF reduced oxidative stress and 
inflammatory response while promoting neural repair by 
reduced tubulin breakdown and increased axon assembly. 
The neuroregenerative effect was coupled with improved 
synaptic transmission [28]. For the first time using this 
post-infectious, clinically relevant RR-EAE model a 
given drug therapy was tested. The effect of PIF on the 
global brain genome was evaluated by two independent 
complementary methods of analysis. In this model the 
damage is caused by the ensuing inflammatory response 
to a transient exposure to bacteria. Thus this model 
likely represents the MS pathology. In classic, EAE 
neuroinflammation practically is only antigen driven. 
Interestingly, we find that PIF regulates both infection 
and inflammation induced genes expression. Irrespective 
whether the smegmatis bacteria is innocuous and promptly 
eliminated by the organism, its foot-print persists >70 
days- evidenced by the resulting chronic inflammation.
PIF primarily affected genes are involved in reducing 
oxidative stress, cell cycle check-point regulation, and 
DNA methylation pathways – which support involvement 
in protective mechanisms. For example, by regulating 
the ubiquitination pathway PIF may prevent protein 
degradation - key for neurodegenerative diseases- i.e. 
prions. Effect on EIF2 related genes reflect amino acids 
that are processed post-mRNA activation supporting 
protein neo-synthesis. The reduction in pro-inflammatory 
CD4+ cells activation may further aid in the neuro-repair 
process. Interestingly, the highest ranking upstream 
regulator of PIF was MYCN and expression of microRNA 
let-7 members is controlled by MYC binding to their 
promoters. This is not surprising as let-7 is down-regulated 
by PIF [26]. Together, these results suggest that the PIF 
protective effects in RR-EAE model may involve similar 
protective mechanisms [26–28]. Notably, PIF affected 
genes associated with diverse neurologic disorders, 
beyond those involved in MS. This raised the possibility 
that similar or the same infectious factor can lead to 
progressive brain inflammation and degeneration. For 
example, increased RPH3A, Ras-related protein Rab-3A 
promotes synaptic vesicle traffic and fusion while aberrant 
interaction with alpha-synuclein leads to aggregates 
found in Huntington chorea [59]. SFRS6 constitutively 
splice/missplice Tau exon-10 causes fronto-temporal 
dementia [52]. VARS gene is involved in development 
of brain malformation [60]. SPG7, ATP-dependent zinc 
metalloprotease is involved in development of spastic 
paraplegia [61, 62] while BRD2 gene microdeletion is 
associated with juvenile myoclonic epilepsy development 
[22]. On the other hand the decreased expression of 
ATPase and ubiquitin genes (ATP6AP2, UBE2e1, and 
Ube2q1) prevent mitochondrial oxidative stress leading 
to Parkinson’s disease, Alzheimer’s and X-linked mental 
retardation. SPG21 is a negative pro-inflammatory CD4+ 
cells regulator that can lead to spastic paraplegia while 
the aberrant PDCD10 expression can be associated with 
the development of cavernous cerebral malformation [63]. 
Several other gene function role needs to be examined in 
future studies. Thus, beyond MS PIF may also protect 
against other inflammatory neurological disorders, this 
possibility is currently being examined.
Recently, astrocytes have been implicated in MS 
pathology and shown to play a key role in myelin synthesis 
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[54]. We found that PIF promoted a key myelin synthesis 
inducer BDNF in primary astrocytes which support the 
potential interactions. Evidencing further astrocytes 
role in neural repair is shown by PIF promoting glucose 
transport (SLC2A1) while reducing oxidative stress related 
genes, confirming the gene array data. The presence of 
PIF- astrocyte interaction in vivo however this needs to be 
confirmed by further study. This is of special interest as 
astrocytes play an important role in blood flow regulation 
and since PIF negatively regulates phospholipase A2, 
activating protein (Plaa) expression (Supplementary Table 
1) involvement in this important process is possible. We 
hypothesize that under basal O2 consumption PIF protects 
against oxidative stress [24] and phospholipase A2 promotes 
vasoconstriction. As O2 consumption rises, vasodilatation 
prevails and through Ca++ flux promotes arachidonic acid 
which via COX-1 action releases PGE2 [53]. Similarly, 
PIF also protected against aortic vascular inflammation 
by preventing macrophage induced atherosclerotic plaque 
formation [21]. Additional support for such hypothesis is 
the high canonical ranking of pathways where hypoxia 
signaling in the cardiovascular system was the second 
rank after protein ubiquitination. The second component 
is microglia as microglia play a key role in inflammatory 
response redirecting towards damage or repair depending 
on the activating agent [64]. In primary microglia cell 
cultures PIF promoted IL10 while reducing the major pro-
inflammatory IFNγ expression providing an important 
dual protective effect [26]. Overall targeting primary 
astrocytes and microglia provides support for the observed 
neurotrophic effects of PIF in the CNS.
PIF protects against ionizing radiation induced 
pathologies locally and systemically where reduced 
oxidative stress and protein damage was evidenced [25]. 
Similarly PIF herein in the brain and recently in the 
spinal cord protects against oxidative stress and protein 
degradation [1, 28]. Brain cancer therapy beyond surgery 
requires radiotherapy which promotes inflammation and 
neurodegeneration. This supports the use of PIF in patients 
with brain cancer aiming to mitigate radiation induced 
damage, not affecting the beneficial anticancer effect, 
while promoting neurorepair [24]. Studies examining this 
hypothesis are currently ongoing.
We acknowledge that a minor flaw of our study is the 
lack of the uninfected control in the study. However, we 
demonstrated previously that control animals injected with 
a control plasmid strain rMSHA compared to rMSp139 
(the active agent) did not cause paralysis [43]. The 
strengths of our study are the multiple dosage paradigm 
used and multiple layers of evidence demonstrating PIF`s 
protective effect.
CONCLUSION
Continuous or intermittent PIF administration 
directly promotes re-myelination while reducing paralysis 
in clinically-realistic MS/neuroinflammation model. 
Promotion of BDNF by cultured astrocytes- support 
possible local myelin synthesis. Local CNS protection 
is coupled with reduced systemic inflammation. PIF 
induced brain Na+/K+/Ca++ ions, amino acid and glucose 
transport is coupled with reduced oxidative stress and 
protein degradation pathways. The physiological PIF 
dose used, is similar to endogenous maternal circulating 
levels where MS symptoms frequently improve [4]. Upon 
completion of the ongoing Phase Ib clinical trial for 
autoimmune disease, phase II clinical trial for PIF testing 
in neuroinflammation/MS is planned.
MATERIALS AND METHODS
Mice, peptides and mycobacterium strain
Eight week-old SJL female mice were purchased 
from Charles River (Calco, Italy) and kept in a 
conventional facility at “Università Cattolica del Sacro 
Cuore” in Rome. All experimental procedures involving 
animals were approved by the internal Ethical Committee 
and by the Italian Ministry for Health. Peptide 139–151 
of proteolipid protein (p139, HSLGKWLGHPDKF) was 
purchased from PRIMM (Milan, Italy) and was >95% 
pure by HPLC, as determined by mass spectrometry. 
Mycobacterium smegmatis Bacteria expressing the 
chimeric protein containing the p139 fused with MPT64 
(rMSp139) was obtained as previously described [43].
Synthetic PIF (PIF)
PIF, MVRIKPGSANKPSDD, and fluorescein 
isothiocyanate-labelled PIF (FITC-PIF) was provided by 
Bio-Synthesis, Inc. (Lewisville, TX). FITC-scrambledPIF-
GRVDPSNKSMPKDIA) Peptide identity was verified 
by matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry and amino-
acid analysis, and the peptides were purified to >95% by 
HPLC, as documented by mass spectrometry.
RR-EAE induction and clinical evaluation
SJL female mice, 8-10 weeks old, were infected 
subcutaneously (s.c.) in the back with 4x106 CFU of 
rMSp139 in PBS 100 µl/mouse. Notably, in this Smegmatis 
model we demonstrated previously that control animals 
injected with a control plasmid strain rMSHA compared 
to rMSp139 (the active agent) did not cause paralysis 
[43]. Clinical signs of EAE were evaluated daily and in 
a blinded fashion according to the following scale 0-5: 
0, no clinical score; 1, loss of tail tone; 2, weak hind leg 
paresis; 3, hind leg paresis; 4, complete paraplegia; and 
5, death or moribund. Intermediate values were assigned 
for incomplete symptoms. Average total score of disease 
(ATSD) was calculated as the average of the sum of daily 
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scores of each mouse. Area under the curve (AUC) at the 
peak,* was calculated using a score of 0.5 as baseline in 
composite experiments [28].
PIF treatment
To test PIF effects we used two different treatment 
regimens. First we tested continuous administration: Mice 
were injected intraperitoneally (i.p.) with PIF (0.75 mg/kg 
or 1.5 mg/kg in PBS 100 μl daily) starting on day 3 after 
infection with rMSp139 until the end of the experiment. 
The control group received vehicle only. Next we tested 
intermittent administration: Mice were injected i.p. with 
PIF (0.75 mg/kg in PBS 100 μl daily) starting at symptom 
onset and continuing until remission of the symptoms. We 
resumed administration at subsequent relapse. Again, the 
control group received PBS vehicle only.
FITC-PIF in the brain (cross intact BBB)
Mice, previously treated with continuous daily 
administration for 3 weeks with PIF 0.75 mg/kg, or PBS 
were tested. By day 62 after infection mice were treated 
with an injection of FITC-PIF 0.75 mg/kg in 100 μl of 
PBS or with vehicle only. An additional negative control 
FITC-scrambled PIF was injected as well. At 3 hours 
after injection mice were sacrificed and the brains were 
analyzed.
Tissue harvesting and brain myelin evaluation
At day 28-30 after EAE induction, mice under deep 
anesthesia (Ketamine 75 µg/Kg, Medetomidine 1 µg/
Kg i.p.) were perfused with 50 ml of PBS and sacrificed. 
Spleen and brain tissue was collected. Tissue was placed in 
nitrogen in cryovials for 10 min and stored at-80C. Given 
that myelin loss is a prominent event in MS we evaluated 
a myelin staining technique [45, 46]. Briefly, fixed brains 
were embedded in paraffin and sectioned into 7µm slices. 
Slides were rinsed in ddH2O, counterstained in Cresyl 
violet (Nissl body staining for neuronal structure and 
gross brain morphology) and Luxol Fast Blue (to reveal 
areas of myelination in the subcortical white matter), 
dehydrated in a series of ethanol baths (95% >100%) 
and xylene, and mounted with Eukitt (Sigma-Aldrich, St. 
Louis, MO). For FITC-PIF localization in the CNS, mice 
were perfused under deep anaesthesia (Ketamine 75 mg/
Kg, Medetomidine 1 mg/Kg i.p.), through the aorta with 
50 ml of PBS, followed by 50 ml of 4% paraformaldehyde 
(VWR international). Brain were removed and immersed 
in the same fixative for 24 hrs. Tissue blocks were 
routinely embedded in paraffin and 10 μm thick slices 
were prepared. Staining have been made automatically 
with the immunostainer Leica Bond RX. In brief, after 
deparaffinization of the slides, the target was retrieved in 
citrate buffer (10 mM; pH 6.0; Leica) for 30 min. A rabbit 
polyclonal antibody against the ionized calcium binding 
adaptor molecule 1 (Iba-1, Abcam, ab5076, 1:100), a 
highly specific marker for microglia, was used to localize 
both resting and activated microglia [26, 27]. Monoclonal 
antibody anti-PIF (1:100, GenWay, San Diego, Ca, USA) 
was used to detect sPIF. After quenching endogenous 
peroxidase activity, slides have been incubated 30min with 
anti-Iba1 antibody, followed by incubation with a rabbit 
anti-goat secondary antibody (DAKO, 1:400, E0466) 
for 15min. An anti-rabbit Poly-HRP IgG polymer was 
then applied to the slides for 15 min at RT, followed by 
application of DAB+ chromogen in buffer substrate for 10 
min (Bond Polymer Refine Detection Kit). Additionally, 
PIF expression was detected using a fluorescent setup. 
After Iba1 staining, slides were blocked with 10% goat 
serum/1% bovine albumin/PBS followed by incubation 
with the anti-sPIF antibody for 1h at RT and then FITC-
labeled streptavidin (1:200, Sigma-Aldrich) for 1h at RT. 
The tissue was finally counterstained with hematoxylin 
and slices were mounted with VECTASHIELD (Mounting 
Medium with DAPI). We acquired images using a BX51 
microscope (Olympus, Tokyo, Japan) with a 20x or 
40x objective and equipped with a digital camera. An 
independent observer acquired sections visual field by 
visual field without overlapping per hemisphere and 
animal for each specific immunostaining blinded to the 
experimental conditions.
Cytokine production and transcription factor 
mRNA expression
Following immunization and PIF or vehicle 
administration, at day 10 of the experiment mice were 
sacrificed and the popliteal lymph nodes (LNs) were 
collected. Then the dissociated 5×106 LN cells/well 
were cultured for 3 hrs in RPMI-1640 medium (Sigma- 
Aldrich, St Louis, MO, USA) supplemented with 2mM 
L-glutamine, 50 μM 2-ME, 50 μg/ml gentamicin (Sigma- 
Aldrich, St Louis, MO, USA) and 0.2% mouse serum. 
LN cells were then re-suspended in RLT buffer for RNA 
extraction. Total mRNA was isolated using RNeasy Mini 
Kit (Qiagen, Valencia, CA) and cDNA was synthesized 
using qScript™ cDNA SuperMix (Quanta BioSciences, 
Inc., Gaithersburg) according to the manufacturer’s 
instructions. Quantification of mRNA was performed 
at 260 nm using NanoDrop 1000 (Thermo Scientific, 
Waltham, MA).
Quantitative mRNA expression
qRT-PCRs were performed using iQ SYBR® Green 
Supermix and an iQ5 Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA). Relative expression levels of 
cytokine and transcription factor mRNAs were normalized 
using 18S as the housekeeping gene and calculated with 
the 2−ΔΔCt method. Samples were loaded in triplicate. 
qRT-PCR was followed by a melting curve to assess 
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presence of specific replicons and primer dimers. The 
following primers (Invitrogen™ Life Technologies, 
Paisley, UK) were used: mouse Interferon (IFN)-γ, 
forward 5′-CAG CAA CAG CAA GGC GAA AAA GG-3′ 
and reverse 5′-TTT CCG CTT CCT GAG GCT GGA T-3′; 
mouse FoxP3, forward 5′-CCT GGT TGT GAG AAG 
GTC TTC G-3′ and reverse 5′-TGC TCC AGA GAC TGC 
ACC ACT T-3′; mouse Interleukin (IL)-6, forward 5′-
ACA CAT GTT CTC TGG GAA ATC GT-3′ and reverse 
5′-AAG TGC ATC ATC GTT GTT CAT ACA-3′; mouse 
IL-12b, forward 5′-GAA GCA CGG CAG CAG AAT-3′ 
and reverse 5′-AGC CAA CCA AGC AGA AGA CA-
3′; mouse IL-13, forward 5′-AAC GGC AGC ATG GTA 
TGG AGT G-3′ and reverse 5′-TGG GTC CTG TAG ATG 
GCA TTG C-3′, mouse IL-17, forward 5′-CAG ACT ACC 
TCA ACC GTT CCA C-3′ and reverse 5′-TCC AGC TTT 
CCC TCC GCA TTG A-3′, mouse IL-23, forward 5′-CAT 
GGG CTA TCA GGG AGT A-3′ and reverse 5′-AAT AAT 
GTG CCC CGT ATC CA-3′, mouse Transforming Growth 
Factor (TGF)-beta, forward 5′-ACC CCC ACT GAT ACG 
CCT GA-3′ and reverse 5′-AGC AGT GAG CGC TGA 
ATC GAA-3′, mouse 18S, forward 5′-CTG CCC TAT 
CAA CTT TCG ATG G-3′ and reverse 5′-CCG TTT CTC 
AGG CTC CCT CTC-3′, mouse IL-10, forward 5′-GCT 
CCT AGA GCT GCG GAC T-3′ and reverse 5′-TGT TGT 
CCA GCT GGT CCT TT-3′, mouse IL-5, forward 5′-CTC 
TGT TGA CAA GCA ATG AGA CG T-3′ and reverse 5′-
TCT TCA GTA TGT CTA GCC CCT G-3′, mouse t-bet 
(tbx21) forward 5′-AGC AAG GAC GGC GAA TGT 
T-3′and reverse 5′-GGG TGG ACA TAT AAG CGG TTC-
3′, mouse RORγ-t forward 5′-CTA CTG AGG AGG ACA 
GGG AG-3′ and reverse 5′-AGT AGG CCA CAT TAC 
ACT GCT-3′, mouse GATA-3 forward 5′-CTC GGC CAT 
TCG TAC ATG GAA-3′ and reverse 5′-GGA TAC CTC 
TGC ACC GTA GC-3′.
T cell receptor repertoire analysis
Repertoire analysis was performed using a 
modification of a described protocol [55]. For the TCR 
spleen repertoire analysis, 107/well splenocytes were 
cultured on 24-well plates in RPMI-1640 medium 
(Sigma- Aldrich, St Louis, MO) supplemented with 2mM 
L-glutamine, 50 μM 2-ME, 50 μg/ml gentamicin (Sigma- 
Aldrich, St Louis, MO, USA) and 0.2% mouse serum in 
the presence or absence of 10 μg/ml p139. After 72 hrs 
splenocytes were re-suspended in RLT buffer for RNA 
extraction. Total mRNA was isolated using RNeasy Mini 
Kit (Qiagen, Hilden, Germany) and cDNA was synthesized 
using qScript™ cDNA SuperMix (Quanta BioSciences, 
Inc., Gaithersburg, MD) according to the manufacturer’s 
instructions. Quantification of mRNA was performed 
at 260 nm using NanoDrop 1000 (Thermo Scientific, 
Waltham, MA). For the immunoscope analysis, cDNA 
was subjected to PCR amplification using a common 
constant β primer (Cβ 5’-CAC TGA TGT TCT GTG TGA 
CAG-3’) in combination with the variable β (Vβ) primer 
previously described [65]. Using 2 µl of this product as a 
template, run-off reactions were performed with a single 
internal fluorescent primer for each Jβ tested [65]. The 
products were then denatured in formalin and analysed on 
a 3130 Genetic Analyzer using Gene Mapper 4.0 (Applied 
Biosystem Foster City, CA, US). Results are reported as 
a relative stimulation index (RSI) [42], obtained from the 
ratio between the normalized peak area of cells stimulated 
with p139 and the normalized peak area of non-stimulated 
cells. T cells carrying a TCR rearrangement are considered 
expanded in a peptide-driven manner when RSI is > 2.
Global gene expression
To detect the global gene changes in the brain 
we performed a gene array. Briefly, 30 mg of brain 
tissue (n=3 each, PIF versus PBS) was excised and 
homogenized in a Fastprep 120 tissue homogenizer (30 s 
at 4.0m/sec) in cell lysis buffer (Qiagen, Hombrechtikon, 
Switzerland). Total RNAs were extracted from cells using 
PureLink RNA Mini Kit (Ambion, Thermo- Fischer 
catalog number 12183018A). Total RNA (250ng) was 
amplified into cRNA using TotalPrep RNA amplification 
kit (AMIL1791, Ambion) following manufacturer’s 
instructions. After amplification, 1.5 µg of cRNA was 
mixed with the hybridization controls and was hybridized 
to MouseRef-8 array (BD-202-0202, Illumina, USA). The 
array was hybridized for 16 hrs in a hybridization oven 
with a rocking platform at 58°C. The array chip then went 
through a series of washes before it was stained with 
streptavidin-Cy3. After the staining, it went through a 
final wash and drying. The array was scanned using the 
Illumina HiScan Scanner.
Preparation and testing of PIF effects on 
of primary mouse astrocytes: Gene array 
validation
PIF’s targeting of microglia in a cell line and 
neurons both in vitro and in vivo was demonstrated [26, 
27]. However, whether PIF targets astrocytes, which 
emerged as an important cell type in neurodegenerative 
diseases such as MS, has not been tested [54]. Astrocyte 
cultures were prepared from 2-day old C57BL/6 mouse 
neonates. Cortices were isolated, stripped of their 
meninges and mechanically dissociated in ice-cold HBSS. 
The resulting cell suspension was then incubated with 
0.05% trypsin for 25 min at 37o C followed by rinsing 
and filtration through a nylon mesh (70-μm pore size). 
The cells were then plated on collagen-coated plates and 
were maintained in astrocyte medium (ThermoFisher 
Scientific). Cells were studied after 2 weeks in culture. 
The effect of PIF 100 or 200nM on BDNF, recognized as 
key for MS therapy, was tested after a 48 hour culture [54]. 
In addition, three genes identified in the brain array were 
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also validated using RT-qPCR, namely SLC2A1 (glucose 
transporter) and HSP90ab1 plus E2f5 related to oxidative 
stress and cell cycle control, respectively). At the end of 
the experiments cells were rinsed, then RNA was extracted 
and processed for RT-qPCR. Fold change was determined 
and compared to control. Data was generated in triplicate 
in three different experiments, setting significance at 
p<0.05.
PIF effect on cytokine expression by primary 
microglia
Primary microglia were obtained from StemCells 
(Newark, Ca). These cells were isolated from 2 day old 
neonate C57BL/6 mouse brain tissues and placed in culture. 
The effect of PIF 0 to 200nM on IFNγ and IL10 expression 
was examined after 48 hours in culture. At the end of the 
experiments cells were rinsed, RNA was extracted and 
processed for qRT-PCR. Fold change was determined and 
compared to control. Data were generated in triplicate in 
3 independent experiments, setting significance at p<0.05.
Real-time quantitative PCR analysis of 
astrocytes and microglia
Total RNA was isolated from cultured astrocytes 
using QIAzol reagent (Qiagen, Valencia, CA) according to 
the manufacturer’s protocol. 0.5 μg of RNA was employed 
to synthesize cDNA by Thermoscript (Invitrogen, Carlsbad, 
CA) with oligo dTprimers. A primer optimization step was 
performed for each set of primers to determine the optimal 
primer concentrations. Primers, 25 µL of 2x SYBR Green 
Master Mix (Invitrogen), and 30 to 100 ng cDNA samples 
were then re-suspended in a total volume of 50 µL PCR 
amplification solution. Reactions were run on an ABI Prism 
7000 Sequence Detection System (Applied Biosystems, 
Foster City, CA). Cycle threshold (Ct) values were obtained 
from the ABI 7000 software. S12 or ß-actin levels were also 
determined for each RNA sample as controls.
Statistical analysis
Statistical analysis of the results was performed, 
when appropriate, with the two-tailed Wilcoxon-Mann-
Whitney test for non-parametric values or with chi-
squared tests, using GraphPad Prism 5.03 (GraphPad 
Software, Inc. La Jolla, USA); p<0.05 was considered 
significant. The output of the limma analysis was used to 
perform gene set enrichment analysis (GSEA) using the 
SetRank method. The key principle of this algorithm is 
that it discards gene sets that have initially been flagged as 
significant, if their significance is only due to the overlap 
with another gene set. It calculates the p-value of a gene 
set using the ranking of its genes in the ordered list of 
p-values as calculated by limma. The following databases 
were searched for significant gene sets: BIOCYC [66], 
Gene Ontology [67], ITFP [68], KEGG [69], LIPID 
MAPS [70], PhosphoSitePlus [51], REACTOME [62], 
and WikiPathways [71].
Pathway ingenuity analysis
Genes found to be significantly different between 
PIF and control (p<0.05, two-tail Student’s t test, n=168) 
were analyzed. We first determined the Z score to identify 
the highest association within the pathways. Further 
use of pathway analysis for ranking gene clusters and 
their association was accomplished by determining the 
statistical value of a pathway and whether the interaction 
led to up- or down-regulation of a given gene cluster.
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